Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Franklin Genomic Advancements Fund W (acc) USD Fonds 113722507 / LU2387455947

5.98 USD
0.11 USD
1.87 %
25.11.2024
NAV

Nettoinventarwert (NAV)

5.98 USD 0.11 USD 1.87 %
Vortag 5.87 USD Datum 25.11.2024

Franklin Genomic Advancements Fund W (acc) USD Fonds Kurs - 1 Jahr

  • 1W
  • 3M
  • 1J
  • 3J
  • 5J
  • MAX

Top Kryptowährungen ETPs

Name ISIN Performance
21Shares Sui Staking ETP CH1360612159 302.92%
21Shares Stacks Staking ETP CH1258969042 227.84%
21Shares Cardano ETP CH1102728750 164.45%
21Shares Ripple XRP ETP CH0454664043 137.47%
21Shares Fantom ETP CH1168929078 102.09%
21Shares Algorand ETP CH1146882316 93.41%
21Shares Injective Staking ETP CH1360612134 18.63%
21Shares Immutable ETP CH1360612142 8.49%
Name ISIN Performance
21Shares Ripple XRP ETP CH0454664043 163.46%
21Shares Stacks Staking ETP CH1258969042 145.10%
21Shares Cardano ETP CH1102728750 116.30%
21Shares Aave ETP CH1135202120 86.40%
21Shares Crypto Basket Equal Weight (HODLV) ETP CH1135202161 49.45%
Name ISIN Performance
21Shares Solana staking ETP CH1114873776 329.69%
21Shares Fantom ETP CH1168929078 211.89%
21Shares Staking Basket Index ETP CH1210548892 170.71%
21Shares Binance BNB ETP CH0496454155 168.82%
21Shares Crypto Basket Equal Weight (HODLV) ETP CH1135202161 162.98%
Name ISIN Performance
21Shares Solana staking ETP CH1114873776 1’696.85%
21Shares Bitcoin Core ETP CH1199067674 479.51%
21Shares Bitcoin ETP CH0454664001 464.90%
21Shares Fantom ETP CH1168929078 410.41%
21Shares Bitcoin Suisse ETP CH0496484640 369.11%

Fundamentaldaten

Valor 113722507
ISIN LU2387455947
Emittent Franklin Templeton International Services
Aufgelegt in Luxembourg
Auflagedatum 15.10.2021
Kategorie Branchen: Gesundheitswesen
Währung USD
Volumen 3’016’047.13
Depotbank J.P. Morgan SE, Luxembourg Branch
Geschäftsjahresende 30.06.
Berichtsstand 25.11.2024

Anlagepolitik

So investiert der Franklin Genomic Advancements Fund W (acc) USD Fonds: The Fund's investment objective is capital appreciation. The Fund invests principally in equity securities of companies that are relevant to the Fund’s investment theme of genomic advancements. Equity securities generally entitle the holder to participate in a company's general operating results. While the Fund invests predominantly in common stocks, it could also invest in preferred stock, convertible securities and warrants on securities.

ETP Performance: Franklin Genomic Advancements Fund W (acc) USD Fonds

Performance 1 Jahr
8.53
Performance 2 Jahre
-4.47
Performance 3 Jahre
-38.41
Performance 5 Jahre -
Performance 10 Jahre -